タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	慢性肝炎・肝硬変の診療ガイド2019
出版社	文光堂
発行日	2019-04-19
著者	一般社団法人日本肝臓学会(編著)
ISBN	9784830621055
ページ数	96
版刷巻号	第1版第1刷
分野	臨床医学：内科肝/胆/膵
閲覧制限	未契約

慢性肝炎・肝硬変診療のスタンダード!最新の情報にアップデートされた待望の改訂版!!日本肝臓学会編集による，一般臨床医のための慢性肝炎・肝硬変診療に役立つガイドブックの最新版。慢性肝炎治療に関しては，新しい薬剤の登場による進歩が著しく，最新の情報にアップデートされ大幅に改訂されている。改訂を続けている日本肝臓学会ガイドラインに沿って，最新の診断と治療の実際を，非専門家にも読みやすく，わかりやすく解説した。肝臓専門医だけでなく，慢性肝炎・肝硬変患者の診療に携わるすべての臨床医，コメディカルにも必携の一冊。

目次

表紙
閲覧
執筆者一覧
ii閲覧
慢性肝炎・肝硬変の診療ガイド執筆委員の利益相反に関して
iii閲覧
序文
iv閲覧
刊行にあたって
v閲覧
Contents
vi閲覧
第1章 B型肝炎
P.1閲覧
- 1 概要
- 2 検査・診断
- 3 経過
- 4 治療
第2章 C 型肝炎
P.23閲覧
- 1 概要
- 2 検査・診断
- 3 経過・予後
- 4 治療
第3章肝硬変
P.49閲覧
- 1 概要
- 2 検査・診断
- 3 経過・合併症
- 4 治療
- 5 肝細胞癌のスクリーニング
索引
P.83閲覧
奥付
閲覧

参考文献

第1章 B型肝炎

P.4 掲載の参考文献

1) Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B : summary of a clinical research workshop. Hepatology 2007 ; 45 : 1056-1075.
pubmed

2) Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 ; 45 : 507-539.
pubmed

3) Yokosuka O, Kurosaki M, Imazeki F, et al. Management of hepatitis B : Consensus of the Japan Society of Hepatology 2009. Hepatol Res 2011 ; 41 : 1-21.
pubmed

4) Lee WM. Hepatitis B virus infection. N Engl J Med 1997 ; 337 : 1733-1745.
pubmed

5) Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010 ; 40 : 1-7.
pubmed

P.8 掲載の参考文献

1) 田中榮司, 池田健次, 泉並木, 他. 肝疾患における肝炎ウイルスマーカーの選択基準 (4版). 日消誌 2006 ; 103 : 1403-1412.
Medical*Online

2) Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 ; 295 : 65-73.

3) Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop : a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009 ; 49 : 1151-1157.

4) Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007 ; 45 : 3942-3947.
pubmed

5) Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus corerelated antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009 ; 81 : 27-33.
pubmed

6) Shinkai N, Tanaka Y, Orito E, et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 2006 ; 36 : 272-276.
pubmed

7) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編). B型肝炎治療ガイドライン (第3. 1版). 2019. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hpatitis_b. (2019年3月参照)

P.12 掲載の参考文献

1) Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B : summary of a clinical research workshop. Hepatology 2007 ; 45 : 1056-1075.
pubmed

2) Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B : AASLD 2018 Hepatitis B Guidance. Hepatology 2018 ; 67 : 1560-1599.
pubmed

3) Yokosuka O, Kurosaki M, Imazeki F, et al. Management of hepatitis B : Consensus of the Japan Society of Hepatology 2009. Hepatol Res 2011 ; 41 : 1-21.
pubmed

4) Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991 ; 100 : 182-188.
pubmed

5) Mochida S, Nakao M, Nakayama N, et al. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol 2016 ; 51 : 999-1010.
pubmed

6) Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma : A Prospective Observational Study. Clin Infect Dis 2015 ; 61 : 719-729.

7) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編). B型肝炎治療ガイドライン (第3. 1版). 2019. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b. (2019年3月参照)

P.21 掲載の参考文献

1) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編). B型肝炎治療ガイドライン (第3. 1版). 2019. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b. (2019年3月参照)

2) Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993 ; 119 : 312-323.
pubmed

3) 西口修平. IFN治療. 矢野右人, 林紀夫, 沖田極 (編). コンセンサス肝疾患 2002 診断・治療と病態, 日本メディカルセンター, 2002, pp.71-77.

4) Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol 2012 ; 47 : 814-822.
pubmed

5) Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016 ; 150 : 134-144.

6) 坪内博仁, 熊田博光, 清澤研道, 他. 免疫抑制・化学療法により発症するB型肝炎対策. 肝臓 2009 ; 50 : 38-42.

7) Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos (t) idenaive chronic hepatitis B patients. J Hepatol 2012 ; 57 : 508-514.

8) Suzuki F, Suzuki Y, Hosaka T, et al. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol 2017 ; 52 : 641-651.
pubmed

9) Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016 ; 1 : 196-206.
pubmed

10) Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016 ; 1 : 185-195.
pubmed

第2章 C 型肝炎

P.29 掲載の参考文献

1) Tanaka J, Koyama T, Mizui M, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 2011 ; 54 : 185-195.

2) Ikeda K, Saitoh S, Kobayashi M, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000 ; 18 : 252-266.
pubmed

3) Tamaki N, Kurosaki M, Kuno A, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015 ; 45 : E82-88.
pubmed

4) Yamazaki T, Joshita S, Umemura T, et al. Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C. Sci Rep 2017 ; 7 : 46705.
pubmed

5) Sasaki R, Yamasaki K, Abiru S, et al. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PLoS One 2015 ; 10 : e0129053.
pubmed

P.31 掲載の参考文献

1) Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009 ; 461 : 798-801.
pubmed

2) Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006 ; 78 : 459-465.

3) Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C : A long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999 ; 29 : 1124-1130.

4) Kobayashi M, Suzuki F, Fujiyama S, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017 ; 89 : 476-483.
pubmed

5) Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017 ; 67 : 933-939.

6) Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients : meta-analysis of observational studies. J Viral Hepat 2007 ; 14 : 697-703.
pubmed

7) Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 2016 ; 3 : 3-14.
pubmed

8) Cacoub P, Desbois AC, Comarmond C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C : a meta-analysis. Gut 2018 ; 67 : 2025-2034.
pubmed

P.46 掲載の参考文献

1) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編). C型肝炎治療ガイドライン (第7版). 2019. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c. (2019年4月参照)

2) Kobayashi M, Suzuki F, Fujiyama S, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017 ; 89 : 476-483.
pubmed

3) Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017 ; 67 : 933-939.

4) Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009 ; 41 : 1105-1109.
pubmed

5) Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 ; 59 : 2083-2091.
pubmed

6) Chayama K, Suzuki F, Suzuki Y, et al. All-oral dual combination of daclatasvir plus asunaprevir compared with telaprevir plus peginterferon alfa/ribavirin in treatment-naive Japanese patients chronically infected with HCV genotype 1b : results from a phase 3 study. Hepatology 2014 ; 60 : 1135A.

7) Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015 ; 15 : 645-653.
pubmed

8) Asahina Y, Itoh Y, Ueno Y, et al. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int 2018 ; 38 : 1552-1561.
pubmed

9) Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial. J Viral Hepat 2014 ; 21 : 762-768.

10) Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients : a randomized phase II/III study. J Gastroenterol 2017 ; 52 : 520-533.
pubmed

11) Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol 2017 ; 53 : 557-565.
pubmed

12) Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 2018 ; 67 : 505-513.
pubmed

13) Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial. J Gastroenterol 2019 ; 54 : 87-95.
pubmed

14) Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 2018 ; 12 : 356-367.
pubmed

15) Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015 ; 62 : 1037-1046.
pubmed

16) Toyota J, Karino Y, Suzuki F, et al. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol 2017 ; 52 : 385-395.
pubmed

17) Ohsawa M, Kato K, Itai K, et al. Standardized prevalence ratios for chronic hepatitis C virus infection among adult Japanese hemodialysis patients. J Epidemiol 2010 ; 20 : 30-39.
pubmed

18) Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients : meta-analysis of observational studies. J Viral Hepat 2007 ; 14 : 697-703.
pubmed

19) Sho T, Suda G, Nagasaka A, et al. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatol Res 2018 ; 48 : 529-538.
pubmed

第3章肝硬変

P.54 掲載の参考文献

1) 青柳豊, 道堯浩二郎, 西口修平, 他. 本邦の肝硬変の成因と現状-第44回日本肝臓学会総会主題ポスター「肝硬変の成因別実態」のまとめ. 恩地森一 (監). 肝硬変の成因別実態 2008, 中外医学社, 2008, pp.1-10.

2) 日本消化器病学会 (編). NAFLD/NASH診療ガイドライン 2014, 南江堂, 2014.

3) Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis. Recommendations on difinition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978 ; 31 : 395-414.

4) 日本門脈圧亢進症学会 (編). 門脈圧亢進症取扱い規約第3版, 金原出版, 2013.

5) 池田一夫, 上村尚, 竹内正博. 行政施策と肝硬変死亡. 東京都立衛生研究所研究年報 1997 ; 48 : 354-359.

6) 小林健一, 岡上武, 清沢研道 (編). 肝硬変の成因別実態 1998, 中外医学社, 1999.

7) 泉並木 (監). 肝硬変の成因別実態 2014, 医学図書出版, 2015.

8) 太田康幸, 原田尚, 小林健一 (編). 肝硬変の成因別実態 1991, 日本医学館, 1992.

9) 堀江義則, 石井裕正, 山岸由幸, 他. わが国におけるアルコール性肝硬変の実態とその進展因子に関する検討. 肝臓 2009 ; 50 : 507-513.

10) 高後裕 (監). 我が国における非B非C肝硬変の実態調査 2011, 響文社, 2012.

P.64 掲載の参考文献

1) 持田智, 中山伸朗, 井戸章雄, 他, 我が国における Acute-On-Chronic Liver Failure (ACLF) の診断基準 (案). 肝臓 2018 ; 59 : 155-161.

2) Jalan R, Gines P, Olson JC, et al. Acute-on chronic liver failure. J Hepatol 2012 ; 57 : 1336-1348.
pubmed

3) Ikeda K, Saitoh S, Kobayashi M, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000 ; 18 : 252-266.
pubmed

P.68 掲載の参考文献

1) Runyon BA, AASLD Practice Guidelines. Management of adult patients with ascites due to cirrhosis : an update. Hepatology 2009 ; 49 : 2087-2107.
pubmed

2) Sherlock S, Dooley J. Chapter 9 Ascites. in Diseases of the Liver and Biliary System, 11th ed, Blackwell Science, Oxford, 2002 ; 127-145.

3) Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig Endosc 2010 ; 22 : 1-9.
pubmed

4) 日本肝癌研究会 (編). 第19回全国原発性肝癌追跡調査報告 (2006～2007), 2014.

5) 恩地森一 (監), 青柳豊, 道堯浩二郎, 西口修平 (編). 肝硬変の成因別実態 2008, 中外医学社, 2008.

6) HRSAホームページ「MELD Calculator」. https://optn.transplant.hrsa.gov/resources/allocationcalculators/meld-calculator/

7) Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma : a new evidence-based approach-the ALBI grade. J Clin Oncol 2015 ; 33 : 550-558.

8) 泉並木 (監), 泉並木, 玉城信治. 全国の集計. 肝硬変の成因別実態 2014, 医学図書出版, 2014.

9) Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma : a large retrospective multicenter cohort study. J Gastroenterol 2015 ; 50 : 350-360.
pubmed

P.77 掲載の参考文献

1) 市田文弘, 小俣政男, 辻孝夫, 他. 慢性肝炎の肝組織診断基準-新犬山分類. 犬山シンポジウム記録刊行会 (編). C型肝炎研究の進歩, 肝炎ウイルスの変異, 犬山分類の再検討. 中外医学社, 1996 ; 183-188.

2) Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 ; 60 : 646-649.

3) Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B : A multicenter retrospective study of 2795 patients. Hepatol Res 2005 ; 32 : 173-184.
pubmed

4) Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999 ; 131 : 174-181.

5) 日本消化器病学会 (編). 肝硬変診療ガイドライン 2015 改訂第2版, 南江堂, 2015.

6) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編). B型肝炎治療ガイドライン (第3. 1版). 2019. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b. (2019年3月参照)

7) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編). C型肝炎治療ガイドライン (第7版). 2019. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c. (2019年4月参照)

8) 厚生労働省難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班. 自己免疫性肝炎 (AIH) 診療ガイドライン (2016年), 2017.

9) 森脇久隆. 肝硬変からの発癌率に及ぼすインターフェロン, SNMC, UDCA, BCAAの影響. 厚生労働科学研究費補助金肝炎等克服緊急対策研究事業 (肝炎分野) 肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究平成21年度総括・分担研究報告書 (研究代表者熊田博光), pp.46-47.

10) Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997 ; 79 : 1494-1500.

11) Omata M, Yoshida H, Toyota J, et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007 ; 56 : 1747-1753.
pubmed

12) Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial. J Gastroenterol 2019 ; 54 : 87-95.
pubmed

13) 児玉浩子, 青木継稔, 有馬正高, 他. Wilson病診療ガイドライン 2015. 日本小児栄養消化器肝臓学会雑誌 2015 ; 29 : 63-119.

14) Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007 ; 23 : 113-120.
pubmed

15) Sakaida I, Terai S, Nakajima K, et al. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis : a post hoc analysis. J Gastroenterol 2017 ; 52 : 229-236.
pubmed

16) 寺井崇二, 田邊規和, 五嶋敦史, 他. 肝性浮腫に対するバソプレシンV2受容体拮抗剤トルバプタンの使用法の提案-肝性浮腫の発生機序から考える-. 肝胆膵 2014 ; 69 : 955-960.
Medical*Online

17) 厚生労働省食品安全部ホームページ「ビブリオ・バルニフィカスに関する Q&A」. http://www.mhlw.go.jp/topics/bukyoku/iyaku/syoku-anzen/qa/060531-1.html

18) Mayo Clinicホームページ「MELD Model」. http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease/meld-model

P.82 掲載の参考文献

1) 日本肝臓学会 (編). 肝癌診療ガイドライン 2017年版, 金原出版, 2017.

2) Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999 ; 131 : 174-181.

3) Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B : A multicenter retrospective study of 2795 patients. Hepatology Res 2005 ; 32 : 173-184.
pubmed

4) Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005 ; 33 : 72-76.
pubmed

5) Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology 2019 ; 156 : 477-491.
pubmed

6) Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017 ; 153 : 996-1005.e1.

7) Nahon P, Layese R, Bourcier V, et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018 ; 155 : 1436-1450.e6.

8) Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009 ; 137 : 110-118.

9) Kuno A, Ikehara Y, Tanaka Y, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013 ; 3 : 1065.
pubmed

10) Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers : pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002 ; 8 : 749-761.
pubmed

11) Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma : a systematic review. Am J Gastroenterol 2006 ; 101 : 513-523.
pubmed

12) Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010 ; 45 : 133-141.
pubmed

13) Chung YE, Park MS, Kim MS, et al. Quantification of superparamagnetic iron oxide-mediated signal intensity change in patients with liver cirrhosis using T2 and T2 ＊ mapping : a preliminary report. J Magn Reson Imaging 2010 ; 31 : 1379-1386.
pubmed

はじめての方へ

個人／法人会員登録のご案内